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cal trials conducted in the United States.1-3 Among these
patients, a significant reduction in hospital stay has been
demonstrated, with early return to preoperative levels of
activity. Enthusiasm for endovascular treatment for the
patient at low risk has also been coupled with the propo-
sition that endovascular therapy provides an ideal
approach for patients in whom standard operative repair
carries an increased risk of perioperative morbidity and
mortality.4 Indeed, endovascular treatment has increased
the proportion of patients now referred for AAA repair by
providing therapy for patients who have been deemed
inoperable because of the presence of significant comorbid
conditions. Nonetheless, the widespread advocacy of
endovascular grafting as a preferred option to open
surgery for potentially all anatomically suitable patients
continues during a period when most studies have
reported outcomes that are largely confined to early inter-
vals after intervention.
This report reviews our mid-term experience with
endovascular AAA repair by examining early and late clin-
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Purpose: As a minimally invasive strategy for the treatment of patients with abdominal aortic aneurysm (AAA), endovascular
repair has been embraced with enthusiasm because of the promise of achieving a durable result with a reduced risk of periop-
erative morbidity and mortality. Our mid-term experience with endovascular AAA repair was assessed by examining early and
late clinical outcome in concurrent cohorts of patients stratified either as low-risk or as at increased-risk for intervention.
Methods: From April 1994 to December 1999, endovascular AAA repair was performed in 104 patients with commercially avail-
able systems. A subset of patients considered at increased risk for intervention (n = 51) were categorized as such based on a pre-
existing history of ischemic coronary artery disease (73%), with documentation of myocardial infarction (57%) or congestive heart
failure (29%), or because of the presence of chronic obstructive pulmonary disease, liver disease, or malignancy.
Results: The perioperative mortality rate (30-day) was 7.8% for patients at increased risk compared with 1.9% among those
classified as low-risk (P = NS). There was no difference between groups in age (72 ± 7 years vs 74 ± 7 years; mean ± SD),
surgical time (221 ± 90 minutes vs 192 ± 68 minutes), blood loss (437 ± 402 mL vs 331 ± 238 mL), postoperative hospital
stay (4.4 ± 2.7 days vs 4.2 ± 2.5 days), or days in the intensive care unit (1.2 ± 1.6 days vs 0.6 ± 1.3 days). Patients at increased
risk of intervention had larger aneurysms than patients at low risk (58 ± 11 mm vs 52 ± 12 mm; P < .05). Stent grafts were
successfully implanted in 47 (92%) patients at increased risk versus 50 (94%) patients at low risk (P = NS). Conversion rates
to open operative repair were similar in increased-risk and low-risk groups at 3.9% and 5.7%, respectively. The initial endoleak
rate was 21% versus 18% based on the first computed tomography performed (either at discharge or 1 month; P = NS). To
date, patients at increased risk have been monitored for 14.6 ± 12.4 months, and patients at low risk have been monitored
for 17.7 ± 15.0 months. Kaplan-Meier analysis for cumulative patient survival demonstrated a reduced probability of survival
among those patients initially classified as at increased risk for intervention (P < .05, Mantel-Cox test). Both cohorts had sim-
ilar 2-year clinical success rates of approximately 75%.
Conclusion: Despite the use of an endovascular approach for aneurysm treatment, the risk of perioperative death and mor-
bidity remains present for all patients including those who have no significant medical comorbidity. Moreover, although clin-
ical success rates are comparable in both patient groups, 2 years after endovascular repair was performed, at least one in four
patients was classified as a clinical failure. Given the continued uncertainty associated with clinical outcome and the need for
close life-long surveillance, caution is dictated in advocating endovascular treatment for the patient who is otherwise consid-
ered an ideal candidate for standard open surgical repair. (J Vasc Surg 2001;33:S70-6.)
With the advent of an endovascular treatment option
for the abdominal aortic aneurysm (AAA), defining an
appropriate strategy for the referral of patients to either
open or endovascular repair remains a complex clinical
endeavor. For example, patients who were otherwise
appropriate surgical candidates for standard open repair
have populated most, if not all, industry-sponsored clini-
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ical outcome in concurrent cohorts of patients stratified
either as patients at low risk, who would otherwise be con-
sidered ideal open surgical candidates, or as those who are
at increased risk for intervention. In these two groups of
patients, we assessed perioperative morbidity and mortal-
ity, technical success, and late clinical success rates and
patient survival.
MATERIAL AND METHODS
Patient selection. Data for 104 consecutive patients
undergoing elective endovascular AAA repair at Emory
University Hospital (Atlanta, Ga) were retrospectively col-
lected from April 1994 through December 1999. An
endovascular program was initially instituted at Emory
University as part of an investigator-sponsored, investiga-
tional trial (Endovascular Technologies, Inc, Menlo Park,
Calif/Guidant, Inc, Indianapolis, Ind). This program
expanded in 1999 to include a second investigational
device (EXCLUDERTM, WL Gore and Associates, Inc,
Flagstaff, Ariz). We have also used the AneuRx
(Medtronic, Inc, Sunnyvale, Calif) endograft system after
its approval by the Food and Drug Administration for
commercial use in September 1999. During the study
period, implanted endografts included the EVT/Guidant
endograft (n = 71), the AneuRx stent graft system (n =
16), and the Excluder endograft (n = 17). The
EVT/Guidant endografts included tube (n = 26), bifur-
cated (n = 33), and aortoiliac endografts combined with a
femorofemoral bypass graft (n = 12). The Gore endografts
were all phase II devices.
Patients were considered at increased risk for inter-
vention if there was (1) documentation for previous
myocardial infarction (MI) or congestive heart failure, (2)
significant respiratory disease as demonstrated by a forced
expiratory volume in 1 second of <1 L/min or a require-
ment for home oxygen therapy, (3) chronic liver disease
with documented cirrhosis or portal hypertension, or (4)
the presence of concurrent or recent malignancy. Of note,
all patients underwent preoperative cardiac risk assessment
that included dobutamine echocardiography or persantine
thallium scanning.
Endograft implantation. All endovascular AAA
repairs were performed in a standard operating depart-
ment with complete angiographic capability by a team of
vascular surgeons and interventional radiologists. The
techniques of transfemoral endovascular AAA prosthesis
implantation have been described previously.1-5
Fluoroscopic guidance (OEC 9600, OEC Medical
Table I. Characteristics defining patients at increased risk
for intervention (n = 51)
Characteristic No. (%)
Congestive heart failure 15 (30)
Myocardial infarction 29 (57)
Respiratory disease* 11 (22)
Chronic liver disease-cirrhosis/portal hypertension† 2 (4)
Malignancy‡ 6 (12)
*Chronic obstructive pulmonary disease documented by pul-
monary function testing with a forced expiratory volume in 1 sec-
ond ≤1 L/min or the need for home oxygen therapy.
†Child’s class B.
‡Primary lung cancer (n = 3), metastatic colon cancer (n = 1;
Duke’s stage D), laryngeal cancer (n = 1), transitional cell carci-
noma of the bladder (n = 1).
Fig 1. Primary (A) and secondary (B) continuing success rates for low-risk () and increased-risk () groups presented by Kaplan-Meier
method. Statistically significant differences in success rates were not observed.
A B

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Systems, Inc, Thousand Oaks, Calif) was used for place-
ment of the endoprosthesis, and most of the procedures
were performed with the patients under general anesthe-
sia. All patients underwent systemic anticoagulation with
100 U/kg heparin. Postimplantation aortography was
performed to assess graft positioning, vessel patency,
periprosthetic leakage, and graft limb stenosis. Type I
endoleaks, leakage around the proximal or distal attach-
ment site, were treated during the operation with addi-
tional endovascular measures. Type II endoleaks, those
through retrograde lumbar or inferior mesenteric arteries,
were observed and monitored with serial CT scans. At the
discretion of the attending physician, this type of endoleak
was treated with coil embolization of the patent collateral
pathway.
Clinical follow-up. Contrast-enhanced CT was per-
formed either in the immediate postoperative period or
within 1 month of endograft placement. Additional imag-
ing studies including CT, duplex ultrasound scanning, and
plain abdominal x-ray evaluation were performed at 6
months, 12 months, and then annually thereafter. If an
endoleak was visualized, more frequent surveillance imag-
ing was performed as clinically indicated.
Definitions. All perioperative complications are
described; however, major morbidity was defined as any
complication that resulted in an increase in hospital stay, a
secondary surgery, or a significant disability. The defini-
tions of technical success, clinical success, and continuing
success as described by the Society for Vascular
Surgery/International Society for Cardiovascular Surgery
(SVS/ISCVS) Ad Hoc Committee on Reporting
Standards for Endovascular AAA Repair were used.6 In
brief, 30-day technical success was defined on an intent-to-
treat basis as successful endograft deployment without
death, need for standard aortic reconstruction for 30 days,
or evidence of persistent (>48 hours) endoleak. Clinical
success was inclusive of those patients who at 6 months
after implantation had spontaneously sealed a persistent
endoleak and had demonstrated no evidence of aneurysm
enlargement. Secondary clinical success was used if addi-
tional endovascular techniques were required to seal an
endoleak. Continuing success was defined as the mainte-
nance of both clinical and technical success without evi-
dence of graft thrombosis, infection, endoleak, or
aneurysm expansion of greater than 0.5 cm. Any late graft
complication that was successfully treated by an endovas-
cular technique was classified as a secondary continuing
success. Other outcomes analyzed included successful graft
deployment irrespective of the presence or absence of
endoleak, surgical time, operative blood loss, duration of
Table II. Comparison of patients at low risk and increased risk undergoing endovascular AAA repair
Characteristic Increased-risk group (n = 51) Low-risk group (n = 53) P value
Age (y) 72.2 ± 7.2 73.8 ± 7.1 NS
AAA size (mm) 58.2 ± 11.3 52.2 ± 11.5 .008
Preprocedure serum creatinine level (mg/dL) 1.2 ± 0.3 1.2 ± 0.3 NS
Operative time (min)* 221 ± 90 192 ± 68 NS
Blood loss (mL)* 437 ± 402 331 ± 238 NS
Postoperative stay (days)* 4.4 ± 2.5 4.2 ± 2.7 NS
ICU stay (days)* 1.2 ± 1.6 0.6 ± 1.3 NS
Mean ± SD.
NS, No statistical significance; ICU, intensive care unit.
*Includes only patients having successful endograft deployment.
Fig 2. Cumulative survival rates for low-risk () and increased-risk () groups presented by Kaplan-Meier method. A statistically sig-
nificant difference in survival in favor of the low-risk group was noted by the log-rank test (P < .038).

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stay in an intensive care unit, length of hospital stay, and
patient survival.
Statistical analysis. Descriptive data are expressed as
mean ± SD. Continuous variables were compared with the
use of the Student t-test. Nominal variables were analyzed
by contingency tables. The Kaplan-Meier method with
Mantel-Cox (log-rank) post-hoc analysis was used to
determine success and survival rates. P < .05 was consid-
ered statistically significant. An SAS statistical package was
used for analysis (Version 5.0, Abacus Concepts, Berkeley,
Calif).
RESULTS
Between April 1994 and December 1999, elective
endovascular repair of infrarenal AAA was carried out on
104 patients, with 51 (49%) procedures conducted in
patients classified as  increased-risk and 53 (51%) proce-
dures performed in patients considered low-risk for major
morbidity or mortality. The incidence of comorbid condi-
tions among patients deemed at increased risk for inter-
vention is presented in Table I. Patient and procedural
characteristics for these two groups are summarized in
Table II, and the types of endografts implanted are
described in Table III.
Notably, cardiac disease was a major indication for the
categorization of patients at increased risk for intervention.
To obtain a more precise determination of the severity of
cardiac disease in our population, additional risk stratifica-
tion of patients was performed with the SVS/ISCVS
Cardiac Grading System.7 In brief, cardiac status is graded
with a 0 to 3 flat scale where grade 0 indicates a patient
with no symptoms and a normal electrocardiogram (ECG);
grade 1 is used for a patient with no symptoms and a his-
tory of a remote MI (>6 months), occult MI by ECG, or
fixed defect on dipyridamole thallium or similar scan; grade
2 is used for the patient with stable angina, the presence of
a significant reversible perfusion defect on dipyridamole
thallium scan, ejection fraction of 25% to 45%, controlled
ectopy/arrhythmia, or compensated congestive heart fail-
ure; and grade 3 is used for patients with unstable angina,
ejection fraction of less than 25%, symptomatic or poorly
controlled ectopy/arrhythmia, poorly compensated or
recurrent congestive heart failure, or MI within 6 months.
Patients in the study classified as low-risk (n = 53) had an
SVS/ISCVS cardiac score of 0, whereas patients catego-
rized at increased risk solely by a history of cardiac disease
had a score of 1.72 ± 0.63 (n = 32). Of note, most patients
with cardiac disease had a score of 2 (53%; 17 of 32) or 3
(9%; 3 of 32).
Technical and clinical success. Endovascular stent
graft deployment was successful in 47 (92%) of 51 of
patients at increased risk and in 50 (94%) of 53 patients at
low risk, with conversion rates of 3.9% and 5.7%, respec-
tively. No intraoperative deaths occurred. Intraoperative
conversions to open repair and/or aborted procedures all
occurred during attempted implantation of EVT/Guidant
endografts and were not clustered during any given time
period. In the increased-risk group, there were two imme-
diate conversions to open repair and two aborted proce-
dures. In the first case the distal attachment hooks of a
tube graft became caught on the aortic bifurcation and
were unable to be released. In the second case, a device
twist was not resolvable with endoluminal techniques.
One aborted procedure occurred in a patient with tortu-
ous, heavily calcified iliac arteries. The patient subse-
quently died of progressive congestive heart failure several
weeks after hospital discharge. The second aborted proce-
dure was also related to an inability to access the
aneurysm. This patient declined open repair and subse-
quently had a fatal aneurysm rupture. A late conversion
also occurred in this group at 30 months. A patient who
underwent implantation with the original EGS (EVT, Inc)
system had attachment system failure in the form of a
hook fracture. This was recognized because of the pres-
ence of a persistent endoleak and aneurysm enlargement.
The results for the low-risk group were similar, with three
conversions. Two were related to iliac artery injury and
another to device malfunction during deployment. Two
Table III. Types of endografts implanted in each group
Increased-risk group Low-risk group 
Graft type (n = 51) (%) (n = 53) (%)
Bifurcated (EVT) 19 (37) 14 (26)
Tube (EVT) 9 (18) 17 (32)
Aortoiliac* (EVT) 9 (18) 3 (6)
AneuRx (Medtronic) 4 (8) 12 (23)
EXCLUDER (Gore) 10 (20) 7 (13)
Conversions† 2 (4) 3 (6)
Aborted procedures† 2 (4) 0 (0)
*Aortoiliac endograft performed in conjunction with contralat-
eral common iliac artery occlusion and femorofemoral cross-over
graft.
†No significant difference when analyzed by Fischer’s exact test.
Table IV. Perioperative (30-day) complications
Increased-risk Low-risk group
Complication group (n = 49) (n = 50)
Wound infection 5 4
Re-exploration for hemostasis 1 1
Myocardial infarction 1 0
Renal failure (dialysis needed) 0 1
Deep venous thrombosis/pulmonary 0 1
embolism
Graft twist* 1 0
Common femoral artery injury 1 1
*Twisting of one limb of a nonsupported bifurcated graft
required treatment with a femorofemoral cross-over graft at the
time of stent graft implantation.
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late conversions occurred in the low-risk group, one a
consequence of a hook fracture identified at 26 months
and the other of a graft infection at 2 months.
The 30-day technical success rates as defined by the
SVS/ISCVS reporting standards were 71% for the
increased-risk group and 76% for the low-risk group (P =
NS). At 1 month after implantation, 9 (21.4%) patients at
increased risk and 9 (18.4%) at low risk had endoleaks
detected by CT imaging. These results remained essen-
tially unchanged at 6 months, with clinical success rates at
6 months of 80% for the patients at increased risk and 77%
for the low-risk cohort. Six patients at increased risk and
two at low risk had spontaneous sealing of their endoleaks.
All remaining endoleaks were observed during this period,
and no further intervention was taken in this regard.
Continuing primary and secondary success as defined by
the SVS/ISCVS reporting standards are represented in
Fig 1 and were approximately 75% at 24 months. Results
were similar for both patient subgroups.
Adjunctive endovascular techniques were used in both
groups to facilitate graft implantation and AAA exclusion.
In five patients at increased risk, one or both limbs of a
bifurcated graft had intraluminal stents placed for fabric
folds observed with either intravascular ultrasound scan-
ning or angiography at the time of endograft deployment.
Intraluminal stents were also placed in 11 patients at low
risk. Internal iliac arteries were unilaterally embolized in
five patients (one at high risk, four at low risk) for the
exclusion of ectatic or aneurysmal common iliac arteries.
Iliac artery dissection was noted in one patient in each
study group at the time of graft implantation and was
treated successfully in both cases with stent coverage.
Complications. The perioperative complication rate
was 18.3% and 16.0% in the increased- and low-risk
groups, respectively (Table IV). All wound infections were
superficial and successfully treated on an outpatient basis
with local wound care and antibiotic therapy. A single case
of renal failure necessitated hemodialysis. Overall, major
morbidity necessitating an increase in hospital stay or sig-
nificant disability occurred in 4% (2 of 49) of patients at
increased risk and 6% (3 of 50) of patients at low risk.
Follow-up. Follow-up data were complete for all
patients, with a mean follow-up interval of 14.6 ± 12.4
months for patients at high risk and 17.7 ± 15.0 months
for the low-risk group. No patient was lost to follow-up.
The perioperative (30-day) mortality rates were 7.8% and
1.9% for the increased-risk and low-risk groups, respec-
tively (P = .2008, Fisher’s exact test). Four perioperative
deaths occurred in the increased-risk group. One death
occurred in a patient who required conversion from
endovascular repair to open repair and one in a patient
who had an aborted procedure and severe coronary artery
disease. The third death occurred in a patient who had a
successful endovascular repair without evidence of postop-
erative endoleak. A malignant arrhythmia was the pre-
sumed cause of death. The fourth patient died of severe
heart failure after hospital discharge. Endograft deploy-
ment had been successful in this patient, and no endoleak
had been detected by CT scanning at the time of dis-
charge. Eight other patients died during the follow-up
period. In the low-risk group, one perioperative and four
late deaths occurred. The sole perioperative death in this
group was due to intraoperative hemorrhage. Kaplan-
Meier cumulative survival curves are shown in Fig 2. The
2-year mortality rates were 27.8% ± 7.3% and 13.1% ±
6.7% for the increased- and low-risk groups, respectively.
A significant difference between the two patient cohorts
was noted by the Mantel-Cox (log-rank) test (P = .038).
None of the reported late deaths in our series were related
to the initial endovascular procedure, device failure, or late
aneurysm rupture.
DISCUSSION
The introduction of endovascular grafting was a mile-
stone in the treatment of patients with AAA in that it pro-
vided a treatment option for those patients with large
aneurysms who had been deemed inoperable because of
the presence of significant medical comorbidities.4 In the
extension of this technology to all patients with aneurys-
mal disease, clinical investigations have confirmed that
compared with open surgery, an early benefit in quality of
life can be achieved, as it relates to reducing hospital stay
and recovery period.1,2 Nonetheless, even minimally inva-
sive interventions may be associated with an adverse early
outcome, and the presumption that an endovascular
approach reduces perioperative mortality in patients at low
risk compared with the results of standard surgery remains
unproven. Moreover, an early benefit in quality of life may
be offset by a lower level of late clinical success that carries
with it a requirement for more intensive long-term sur-
veillance, increased rates of reintervention, and higher
costs and psychologic stress. Thus, in advocating endovas-
cular treatment for patients who are at low risk for opera-
tive repair, a critical analysis of late outcomes is required.
In our retrospective analysis, patients classified at low
risk for intervention with accepted clinical and laboratory
criteria exhibited a 30-day mortality rate of 1.9% after
endovascular intervention. This result is of particular
interest in the context of a recent review of open aortic
surgery performed on 856 patients at our institution
between 1986 and 1996.8 The in-hospital mortality rate
was 1.3%, with a major complication rate of 15.9%. Thus,
although the data generated by these two distinct reviews
at the Emory University Hospital are not strictly compa-
rable, our experience suggests that in the patient at low
risk, endovascular treatment of the infrarenal AAA is not
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associated with a reduction in perioperative mortality
compared with standard surgical repair.
Many reports, nevertheless, confirm that endovascular
strategies do offer unique advantages among those
patients whose comorbid conditions increase the risk of
major complications including death. For example, May et
al9 compared outcomes of patients treated concurrently
with either open or endovascular repair. Although more
than 40% of patients treated with endografts had been
declined open repair because of comorbid illness, no sig-
nificant difference in perioperative mortality rates or long-
term survival was observed. In addition, Chuter at al10
observed a 30-day mortality rate of 1.7% in their review of
patients treated by endovascular approaches that had oth-
erwise been refused conventional AAA repair. In their
patient population, coronary artery disease was present in
81%, congestive heart failure in 34%, and respiratory dis-
ease in 49%. These reports compare favorably with pub-
lished studies of conventional open aneurysmectomy in
the patient at high risk that have been associated with
mortality rates of up to 40%.11-13
Our review does reemphasize, however, that conver-
sion to an open repair and the aborting of an endograft
procedure may not be well tolerated among those
patients with significant comorbidities. This is consistent
with results reported by May et al,9,14 who have noted
mortality rates of 18% to 43% when primary conversion
was required for patients considered at prohibitive risk for
standard surgery. It is our view that the prolonged anes-
thesia time and the blood loss incurred during a prelimi-
nary attempt at endovascular repair before conversion are
important contributing factors to these poor results.
Therefore a cautious approach should be adopted in rec-
ommending endovascular repair for the patient at high
risk in the presence of anatomic constraints, which
might reduce the potential for successful endograft
deployment.
With SVS/ISCVS recommended reporting standards,
30-day primary technical success, 6-month clinical success,
and 24-month primary and secondary continuing clinical
success rates were all approximately 75% in both study sub-
groups. Our 30-day primary technical success rate is simi-
lar to the 77% rate reported by Zarins et al2 for 190
patients treated as part of the multicenter Medtronic
AneuRx stent graft trial. Likewise, our 24-month success
rate is comparable to that recently reported by May et al15
for second-generation endovascular prostheses used in 148
patients. Thus, although these results are encouraging and
will undoubtedly improve in coming years, the success of
endovascular repair remains uncertain in a significant pro-
portion of patients. Two years after endograft implanta-
tion, 25% of all patients were classified as failures with the
SVS/ISCVS reporting standards definition.6 Therefore, in
advocating an aggressive approach for endovascular inter-
vention in the patient who is an otherwise ideal surgical
candidate, it is also important to recognize that significant
limitations to endovascular repair remain. Moreover, the
impact of this failure rate on increasing costs and reducing
patient quality of life is probably significant but admittedly
was not defined in this report.
It is notable that all reported late deaths in our series
were unrelated to the initial endovascular procedure,
device failure, or late aneurysm rupture. Although late
survival was significantly compromised in those patients
who were deemed at increased-risk for intervention, 75%
were alive at 2 years. These results are not unexpected, and
others have reported similar late mortality rates for
patients initially considered poor surgical candidates.10
Nonetheless, all of this suggests that the benefit of
endovascular repair may be limited for patients who have
a compromised life expectancy. In this regard patients with
a concomitant history of recent or concurrent malignant
disease are a subgroup of particular interest. Of the six
patients in this group, one died of progressive cancer 12
months after endovascular AAA repair. However, the five
remaining patients were alive at the time of last follow-up
(11.4 ± 8.0 months). Thus, given the imprecision in pre-
dicting the risk of AAA rupture and long-term survival
either in response to cancer therapy or other major med-
ical illness, decisions to proceed with endovascular repair
must be carefully individualized. In this regard, we
presently advocate endovascular intervention for the
patient with significant medical comorbidity only when
aneurysm size is equal to or exceeds 6 cm in diameter and
patient life expectancy is estimated to exceed 2 years. We
believe this to be a prudent recommendation given respec-
tive annual rates of rupture of approximately 6.6% and
19% for untreated patients with 5.7-cm and 7.0-cm diam-
eter aortic aneurysms16 and our combined major morbid-
ity and 30-day mortality rate of 12% for the patient at
increased risk for intervention.
In summary, our analysis suggests that endovascular
aneurysm repair currently remains most appropriate for
those patients with large aneurysms who are otherwise
prohibitive operative candidates. It is significant that
endovascular grafting provides these patients with a treat-
ment option when one was not previously available.
Advocating endovascular treatment for the patient who is
at low risk for standard operative intervention remains
problematic. Although clinical success can be achieved in
most patients, inadequate results continue to be observed
in a significant proportion. In deciding on a course of
treatment, an informed decision on the part of the patient
requires a consideration of these data and an appreciation
that endovascular aortic aneurysm repair remains in a rel-
atively early stage of development.
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